Literature DB >> 27172175

Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection - Cherokee Nation, 2012-2015.

Jorge Mera, Claudia Vellozzi, Susan Hariri, Hélène Carabin, Douglas A Drevets, Anna Miller, Brigg Reilley, Whitney Essex, David Gahn, Lisa Lyons, Jessica Leston, John W Ward.   

Abstract

An estimated 3.5 million persons in the United States are living with hepatitis C virus (HCV) infection, resulting in approximately 20,000 deaths each year, primarily from cirrhosis or hepatocellular carcinoma (1,2). American Indian/Alaska Native (AI/AN) populations have the highest incidence of acute HCV infection among all U.S. racial/ethnic groups and are at greater risk for HCV-related mortality compared with the general population (3). In 2013, new antiviral drugs became available that make possible 8-12 week treatment regimens with fewer adverse events and are able to achieve sustained virologic response (SVR) in >90% of treated patients (4), equivalent to a cure of HCV infection. Also of note, HCV testing recommendations were expanded in 2012 by CDC and in 2013 by the U.S. Preventive Services Task Force to include one-time testing of persons born during 1945-1965 (the "baby boomer" cohort) in addition to anyone at increased risk for HCV infection (5,6). Given the availability of new HCV drugs, expanded testing recommendations, and high incidence of HCV infection in AI/AN populations, in October 2012, Cherokee Nation Health Services (CNHS) implemented a tribal HCV testing policy.* As part of the policy, CNHS added a reminder in the electronic health record (EHR) for clinical decision support and provided HCV education to primary care clinicians. From October 2012 to July 2015, among 92,012 persons with at least one CNHS clinic encounter, the cumulative number who received HCV screening for the first time increased from 3,337 (3.6%) to 16,772 (18.2%). The largest percentage of HCV screening was among persons born during 1945-1965. Of 715 persons who tested positive for HCV antibodies, 488 (68.3%) were tested for HCV RNA; among those 488 persons, 388 (79.5%) were RNA positive and were thus confirmed to have chronic HCV infection. Treatment was initiated for 223 (57.5%) of the 388 with chronic infection; 201 (90.1%) completed treatment, of whom 180 (89.6%) achieved SVR. CNHS has successfully increased HCV testing and treatment and is now collaborating with CDC and other external partners to develop an HCV elimination program for the Cherokee Nation that might serve as a model for similar settings.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27172175     DOI: 10.15585/mmwr.mm6518a2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  19 in total

1.  Hepatitis C-Related Mortality Among American Indian/Alaska Native Persons in the Northwestern United States, 2006-2012.

Authors:  Sarah M Hatcher; Sujata Joshi; Byron F Robinson; Thomas Weiser
Journal:  Public Health Rep       Date:  2019-11-25       Impact factor: 2.792

Review 2.  Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.

Authors:  Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson
Journal:  Hepatology       Date:  2018-11-06       Impact factor: 17.425

3.  Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers.

Authors:  Monica A Konerman; Mary Thomson; Kristen Gray; Meghan Moore; Hetal Choxi; Elizabeth Seif; Anna S F Lok
Journal:  Hepatology       Date:  2017-09-14       Impact factor: 17.425

4.  Global Elimination of Hepatitis C Virus.

Authors:  John W Ward
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-10

5.  Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.

Authors:  Alexander J Millman; Noele P Nelson; Claudia Vellozzi
Journal:  Curr Epidemiol Rep       Date:  2017-04-20

6.  Disparities in Cancer Incidence and Trends among American Indians and Alaska Natives in the United States, 2010-2015.

Authors:  Stephanie C Melkonian; Melissa A Jim; Donald Haverkamp; Charles L Wiggins; Jeffrey McCollum; Mary C White; Judith S Kaur; David K Espey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-10       Impact factor: 4.254

7.  Hepatitis C Treatment Cascade in a Federally Qualified Health Center.

Authors:  David M Hachey; John T Holmes; Nicki L Aubuchon-Endsley
Journal:  J Community Health       Date:  2020-04

8.  A Surveillance-Based Hepatitis C Care Cascade, New York City, 2017.

Authors:  Miranda S Moore; Angelica Bocour; Fabienne Laraque; Ann Winters
Journal:  Public Health Rep       Date:  2018-06-14       Impact factor: 2.792

Review 9.  Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020.

Authors:  Jordan J Feld; John W Ward
Journal:  Hepatol Commun       Date:  2021-05-03

10.  Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study.

Authors:  Te-Sheng Chang; Kao-Chi Chang; Wei-Ming Chen; Nien-Tzu Hsu; Chih-Yi Lee; Yu-Chih Lin; Wei-Cheng Huang; Wen-Nan Chiu; Jin-Hung Hu; Tung-Jung Huang; Mei-Yen Chen; Sheng-Nan Lu
Journal:  BMJ Open       Date:  2021-07-07       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.